Skip to content

Journal of Advances in Medicine and Pharmaceutical Sciences

ISSN 2963-4253

2 papers in the library · publishing 2025-2026

Papers

Phytochemical and Neuropharmacological Evaluation of Banisteriopsis caapi, Paullinia cupana, and Turnera diffusa for Potential Anti-Addiction Activity

Journal of Advances in Medicine and Pharmaceutical Sciences May 24, 2026 Fernando Benevenuto, Iscia Martha Franco, Antonio Eizirik et al.

Harmine, caffeine, and damianin—compounds from three Brazilian medicinal plants—show multi-target neuropharmacological activity that could help treat addiction. Computational docking predicted harmine as a selective D2 receptor partial agonist (−10.2 kcal/mol), caffeine as a moderate 5-HT2A modulator (−8.1 kcal/mol), and damianin as a GABA-A agonist-like compound (−9.5 kcal/mol). Network simulations suggested synergistic modulation of dopaminergic, serotonergic, and GABAergic pathways. ADMET profiles indicated favorable brain permeability and oral bioavailability, though harmine showed moderate CYP2D6 inhibition. The findings support a triadic pharmacodynamic model for mitigating craving and withdrawal, but require further validation.

Exploratory Clinical Study on Controlled álak Microdosing for Post-Detoxification Recovery

Journal of Advances in Medicine and Pharmaceutical Sciences November 27, 2025 Roland Mario, Festin Bermudez, Mary Fresthel et al.

Controlled microdosing of álak, a traditional Filipino distilled spirit, may help stabilize nervous system function in people recovering from methamphetamine dependence. In an exploratory clinical study, twelve post-detoxification patients received 5–10 ml of álak (≤10% ethanol) daily for 14 days under medical supervision. Eight of the twelve participants (66.7%) showed marked improvements in sleep continuity, reduced tremors, and lower anxiety scores (mean anxiety reduction 23.4%). No signs of intoxication, craving substitution, or liver distress occurred; one participant reported a mild headache that resolved. These preliminary findings suggest potential GABAergic modulatory effects that could aid neurophysiological stabilization during methamphetamine recovery, warranting further research.